Sutro Biopharma Current Ratio 2017-2021 | STRO

Sutro Biopharma current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Sutro Biopharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.28B $0.03B 10.63
2021-03-31 $0.27B $0.02B 11.74
2020-12-31 $0.38B $0.03B 12.78
2020-09-30 $0.29B $0.03B 9.77
2020-06-30 $0.26B $0.04B 7.29
2020-03-31 $0.13B $0.03B 3.98
2019-12-31 $0.13B $0.03B 3.90
2019-09-30 $0.14B $0.04B 3.78
2019-06-30 $0.16B $0.04B 4.49
2019-03-31 $0.18B $0.03B 5.67
2018-12-31 $0.21B $0.04B 5.76
2018-09-30 $0.13B $0.04B 3.45
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.00B 0.00
2016-12-31 $0.05B $0.05B 0.99
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.877B $0.043B
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86